STAAR Surgical Patient Awareness Campaign Launched In New York - Seite 3

Important Safety Information for EVO ICL

The EVO Visian ICL lens is intended to correct/reduce nearsightedness between -3.0 D up to -20.0 D and treat astigmatism from 1.0 D to 4.0 D. If you have nearsightedness within these ranges, EVO Visian ICL surgery may improve your distance vision without eyeglasses or contact lenses. Because the EVO Visian ICL corrects for distance vision, it does not eliminate the need for reading glasses, you may require them at some point, even if you have never worn them before. Since implantation of the EVO Visian ICL is a surgical procedure, before considering EVO Visian ICL surgery you should have a complete eye examination and talk with your eye care professional about EVO Visian ICL surgery, especially the potential benefits, risks, and complications. You should discuss the time needed for healing after surgery. Complications, although rare, may include need for additional surgical procedures, inflammation, loss of cells from the back surface of the cornea, increase in eye pressure, and cataracts. You should NOT have EVO Visian ICL surgery if your doctor determines that 1) the shape of your eye is not appropriate; 2) you do not meet the minimum endothelial cell density for your age at the time of implantation; 3) you have moderate to severe glaucoma; 4) your vision is not stable; or 5) if you are pregnant or nursing.

For additional information with potential benefits, risks and complications please visit EVOICL.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220914005180/en/

The Staar Surgical Stock at the time of publication of the news with a fall of -1,38 % to 92,70EUR on Tradegate stock exchange (13. September 2022, 22:27 Uhr).